The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
Revenues for Roche Diagnostics totaled CHF 6.26 billion for H1, driven primarily by demand for immunodiagnostic solutions.
The company's revenues totaled $6.08 billion, up from $4.99 billion during Q2 of 2017.
The firm said that its average revenue per clinical genetic test decreased by almost 4 percent to $318, primarily due to changes in Medicare reimbursement and regulation.
The firm booked $484 million in revenues for Alere rapid diagnostics in the quarter, led by sales for infectious disease and cardiometabolic testing.
The firm provided full-year 2018 revenue and adjusted earnings guidance that fell below Wall Street's expectations.
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
Based on the growth in test volume and revenue, the company increased its volume and revenue guidance for the year.
Rapid immunoassay product revenues — including sales from the firm's QuickVue, Sofia, and Eye Health products — rose 40 percent year over year.
Researchers uncovered the HIV virus within a tissue sample collected in 1966, the Atlantic reports.
Nature News reports there are a handful of clinical trials underway to evaluate vaginal microbiome seeding of newborns born via caesarian section.
The Washington Post writes that humans may have contributed to the extinction of cave bears some 20,000 years ago.
In PLOS this week: gene variant may protect against trypanosomiasis, GLIS3 role in type 2 diabetes, and more.